nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—Ageusia—Cisplatin—testicular cancer	0.0357	0.0357	CcSEcCtD
Mepenzolate—Urinary retention—Ifosfamide—testicular cancer	0.0232	0.0232	CcSEcCtD
Mepenzolate—Ageusia—Epirubicin—testicular cancer	0.0183	0.0183	CcSEcCtD
Mepenzolate—Confusional state—Chlorambucil—testicular cancer	0.0183	0.0183	CcSEcCtD
Mepenzolate—Ageusia—Doxorubicin—testicular cancer	0.017	0.017	CcSEcCtD
Mepenzolate—Feeling abnormal—Chlorambucil—testicular cancer	0.0149	0.0149	CcSEcCtD
Mepenzolate—Urticaria—Chlorambucil—testicular cancer	0.0144	0.0144	CcSEcCtD
Mepenzolate—Constipation—Vinblastine—testicular cancer	0.0142	0.0142	CcSEcCtD
Mepenzolate—Confusional state—Bleomycin—testicular cancer	0.0141	0.0141	CcSEcCtD
Mepenzolate—Anaphylactic shock—Bleomycin—testicular cancer	0.014	0.014	CcSEcCtD
Mepenzolate—Vision blurred—Ifosfamide—testicular cancer	0.0138	0.0138	CcSEcCtD
Mepenzolate—Feeling abnormal—Vinblastine—testicular cancer	0.0137	0.0137	CcSEcCtD
Mepenzolate—Hypersensitivity—Chlorambucil—testicular cancer	0.0133	0.0133	CcSEcCtD
Mepenzolate—Asthenia—Chlorambucil—testicular cancer	0.013	0.013	CcSEcCtD
Mepenzolate—Palpitations—Ifosfamide—testicular cancer	0.013	0.013	CcSEcCtD
Mepenzolate—Hypersensitivity—Vinblastine—testicular cancer	0.0122	0.0122	CcSEcCtD
Mepenzolate—Confusional state—Ifosfamide—testicular cancer	0.0121	0.0121	CcSEcCtD
Mepenzolate—Anaphylactic shock—Ifosfamide—testicular cancer	0.012	0.012	CcSEcCtD
Mepenzolate—Vision blurred—Cisplatin—testicular cancer	0.0119	0.0119	CcSEcCtD
Mepenzolate—Asthenia—Vinblastine—testicular cancer	0.0119	0.0119	CcSEcCtD
Mepenzolate—Feeling abnormal—Bleomycin—testicular cancer	0.0115	0.0115	CcSEcCtD
Mepenzolate—Vomiting—Chlorambucil—testicular cancer	0.0115	0.0115	CcSEcCtD
Mepenzolate—Urticaria—Bleomycin—testicular cancer	0.0111	0.0111	CcSEcCtD
Mepenzolate—Dizziness—Vinblastine—testicular cancer	0.011	0.011	CcSEcCtD
Mepenzolate—Feeling abnormal—Dactinomycin—testicular cancer	0.0108	0.0108	CcSEcCtD
Mepenzolate—Nausea—Chlorambucil—testicular cancer	0.0108	0.0108	CcSEcCtD
Mepenzolate—Somnolence—Ifosfamide—testicular cancer	0.0106	0.0106	CcSEcCtD
Mepenzolate—Vomiting—Vinblastine—testicular cancer	0.0106	0.0106	CcSEcCtD
Mepenzolate—Headache—Vinblastine—testicular cancer	0.0104	0.0104	CcSEcCtD
Mepenzolate—Anaphylactic shock—Cisplatin—testicular cancer	0.0103	0.0103	CcSEcCtD
Mepenzolate—Hypersensitivity—Bleomycin—testicular cancer	0.0103	0.0103	CcSEcCtD
Mepenzolate—Constipation—Ifosfamide—testicular cancer	0.0102	0.0102	CcSEcCtD
Mepenzolate—Tachycardia—Cisplatin—testicular cancer	0.0101	0.0101	CcSEcCtD
Mepenzolate—Asthenia—Bleomycin—testicular cancer	0.0101	0.0101	CcSEcCtD
Mepenzolate—Feeling abnormal—Ifosfamide—testicular cancer	0.00987	0.00987	CcSEcCtD
Mepenzolate—Nausea—Vinblastine—testicular cancer	0.00986	0.00986	CcSEcCtD
Mepenzolate—Hypersensitivity—Dactinomycin—testicular cancer	0.00963	0.00963	CcSEcCtD
Mepenzolate—Confusional state—Etoposide—testicular cancer	0.00954	0.00954	CcSEcCtD
Mepenzolate—Urticaria—Ifosfamide—testicular cancer	0.00952	0.00952	CcSEcCtD
Mepenzolate—Anaphylactic shock—Etoposide—testicular cancer	0.00946	0.00946	CcSEcCtD
Mepenzolate—Abdominal distension—Epirubicin—testicular cancer	0.00939	0.00939	CcSEcCtD
Mepenzolate—Asthenia—Dactinomycin—testicular cancer	0.00938	0.00938	CcSEcCtD
Mepenzolate—Tachycardia—Etoposide—testicular cancer	0.00923	0.00923	CcSEcCtD
Mepenzolate—Erectile dysfunction—Methotrexate—testicular cancer	0.00918	0.00918	CcSEcCtD
Mepenzolate—Vomiting—Bleomycin—testicular cancer	0.00891	0.00891	CcSEcCtD
Mepenzolate—Drowsiness—Methotrexate—testicular cancer	0.00888	0.00888	CcSEcCtD
Mepenzolate—Hypersensitivity—Ifosfamide—testicular cancer	0.00883	0.00883	CcSEcCtD
Mepenzolate—Abdominal distension—Doxorubicin—testicular cancer	0.00869	0.00869	CcSEcCtD
Mepenzolate—Asthenia—Ifosfamide—testicular cancer	0.00859	0.00859	CcSEcCtD
Mepenzolate—Feeling abnormal—Cisplatin—testicular cancer	0.00851	0.00851	CcSEcCtD
Mepenzolate—Somnolence—Etoposide—testicular cancer	0.00841	0.00841	CcSEcCtD
Mepenzolate—Nausea—Bleomycin—testicular cancer	0.00833	0.00833	CcSEcCtD
Mepenzolate—Drowsiness—Epirubicin—testicular cancer	0.00831	0.00831	CcSEcCtD
Mepenzolate—Vomiting—Dactinomycin—testicular cancer	0.00831	0.00831	CcSEcCtD
Mepenzolate—Constipation—Etoposide—testicular cancer	0.00809	0.00809	CcSEcCtD
Mepenzolate—Dizziness—Ifosfamide—testicular cancer	0.00792	0.00792	CcSEcCtD
Mepenzolate—Feeling abnormal—Etoposide—testicular cancer	0.0078	0.0078	CcSEcCtD
Mepenzolate—Nausea—Dactinomycin—testicular cancer	0.00776	0.00776	CcSEcCtD
Mepenzolate—Drowsiness—Doxorubicin—testicular cancer	0.00769	0.00769	CcSEcCtD
Mepenzolate—Vomiting—Ifosfamide—testicular cancer	0.00762	0.00762	CcSEcCtD
Mepenzolate—Hypersensitivity—Cisplatin—testicular cancer	0.00761	0.00761	CcSEcCtD
Mepenzolate—Urticaria—Etoposide—testicular cancer	0.00752	0.00752	CcSEcCtD
Mepenzolate—Asthenia—Cisplatin—testicular cancer	0.00741	0.00741	CcSEcCtD
Mepenzolate—Nausea—Ifosfamide—testicular cancer	0.00711	0.00711	CcSEcCtD
Mepenzolate—Hypersensitivity—Etoposide—testicular cancer	0.00697	0.00697	CcSEcCtD
Mepenzolate—Asthenia—Etoposide—testicular cancer	0.00679	0.00679	CcSEcCtD
Mepenzolate—Vomiting—Cisplatin—testicular cancer	0.00657	0.00657	CcSEcCtD
Mepenzolate—Vision blurred—Methotrexate—testicular cancer	0.00654	0.00654	CcSEcCtD
Mepenzolate—Tension—Epirubicin—testicular cancer	0.00638	0.00638	CcSEcCtD
Mepenzolate—Nervousness—Epirubicin—testicular cancer	0.00631	0.00631	CcSEcCtD
Mepenzolate—Dizziness—Etoposide—testicular cancer	0.00626	0.00626	CcSEcCtD
Mepenzolate—Nausea—Cisplatin—testicular cancer	0.00613	0.00613	CcSEcCtD
Mepenzolate—Vision blurred—Epirubicin—testicular cancer	0.00612	0.00612	CcSEcCtD
Mepenzolate—Vomiting—Etoposide—testicular cancer	0.00602	0.00602	CcSEcCtD
Mepenzolate—Headache—Etoposide—testicular cancer	0.00593	0.00593	CcSEcCtD
Mepenzolate—Tension—Doxorubicin—testicular cancer	0.0059	0.0059	CcSEcCtD
Mepenzolate—Nervousness—Doxorubicin—testicular cancer	0.00584	0.00584	CcSEcCtD
Mepenzolate—Palpitations—Epirubicin—testicular cancer	0.00574	0.00574	CcSEcCtD
Mepenzolate—Confusional state—Methotrexate—testicular cancer	0.00571	0.00571	CcSEcCtD
Mepenzolate—Anaphylactic shock—Methotrexate—testicular cancer	0.00567	0.00567	CcSEcCtD
Mepenzolate—Vision blurred—Doxorubicin—testicular cancer	0.00567	0.00567	CcSEcCtD
Mepenzolate—Nausea—Etoposide—testicular cancer	0.00562	0.00562	CcSEcCtD
Mepenzolate—Dry mouth—Epirubicin—testicular cancer	0.00541	0.00541	CcSEcCtD
Mepenzolate—Confusional state—Epirubicin—testicular cancer	0.00535	0.00535	CcSEcCtD
Mepenzolate—Palpitations—Doxorubicin—testicular cancer	0.00531	0.00531	CcSEcCtD
Mepenzolate—Anaphylactic shock—Epirubicin—testicular cancer	0.0053	0.0053	CcSEcCtD
Mepenzolate—Tachycardia—Epirubicin—testicular cancer	0.00518	0.00518	CcSEcCtD
Mepenzolate—Insomnia—Methotrexate—testicular cancer	0.00513	0.00513	CcSEcCtD
Mepenzolate—Somnolence—Methotrexate—testicular cancer	0.00504	0.00504	CcSEcCtD
Mepenzolate—Dry mouth—Doxorubicin—testicular cancer	0.00501	0.00501	CcSEcCtD
Mepenzolate—Confusional state—Doxorubicin—testicular cancer	0.00495	0.00495	CcSEcCtD
Mepenzolate—Anaphylactic shock—Doxorubicin—testicular cancer	0.00491	0.00491	CcSEcCtD
Mepenzolate—Insomnia—Epirubicin—testicular cancer	0.0048	0.0048	CcSEcCtD
Mepenzolate—Tachycardia—Doxorubicin—testicular cancer	0.00479	0.00479	CcSEcCtD
Mepenzolate—Somnolence—Epirubicin—testicular cancer	0.00471	0.00471	CcSEcCtD
Mepenzolate—Feeling abnormal—Methotrexate—testicular cancer	0.00467	0.00467	CcSEcCtD
Mepenzolate—Constipation—Epirubicin—testicular cancer	0.00453	0.00453	CcSEcCtD
Mepenzolate—Urticaria—Methotrexate—testicular cancer	0.0045	0.0045	CcSEcCtD
Mepenzolate—Insomnia—Doxorubicin—testicular cancer	0.00444	0.00444	CcSEcCtD
Mepenzolate—Feeling abnormal—Epirubicin—testicular cancer	0.00437	0.00437	CcSEcCtD
Mepenzolate—Somnolence—Doxorubicin—testicular cancer	0.00436	0.00436	CcSEcCtD
Mepenzolate—Urticaria—Epirubicin—testicular cancer	0.00421	0.00421	CcSEcCtD
Mepenzolate—Constipation—Doxorubicin—testicular cancer	0.0042	0.0042	CcSEcCtD
Mepenzolate—Hypersensitivity—Methotrexate—testicular cancer	0.00417	0.00417	CcSEcCtD
Mepenzolate—Asthenia—Methotrexate—testicular cancer	0.00407	0.00407	CcSEcCtD
Mepenzolate—Feeling abnormal—Doxorubicin—testicular cancer	0.00404	0.00404	CcSEcCtD
Mepenzolate—Hypersensitivity—Epirubicin—testicular cancer	0.00391	0.00391	CcSEcCtD
Mepenzolate—Urticaria—Doxorubicin—testicular cancer	0.0039	0.0039	CcSEcCtD
Mepenzolate—Asthenia—Epirubicin—testicular cancer	0.0038	0.0038	CcSEcCtD
Mepenzolate—Dizziness—Methotrexate—testicular cancer	0.00375	0.00375	CcSEcCtD
Mepenzolate—Hypersensitivity—Doxorubicin—testicular cancer	0.00362	0.00362	CcSEcCtD
Mepenzolate—Vomiting—Methotrexate—testicular cancer	0.0036	0.0036	CcSEcCtD
Mepenzolate—Headache—Methotrexate—testicular cancer	0.00355	0.00355	CcSEcCtD
Mepenzolate—Asthenia—Doxorubicin—testicular cancer	0.00352	0.00352	CcSEcCtD
Mepenzolate—Dizziness—Epirubicin—testicular cancer	0.00351	0.00351	CcSEcCtD
Mepenzolate—Vomiting—Epirubicin—testicular cancer	0.00337	0.00337	CcSEcCtD
Mepenzolate—Nausea—Methotrexate—testicular cancer	0.00337	0.00337	CcSEcCtD
Mepenzolate—Headache—Epirubicin—testicular cancer	0.00332	0.00332	CcSEcCtD
Mepenzolate—Dizziness—Doxorubicin—testicular cancer	0.00324	0.00324	CcSEcCtD
Mepenzolate—Nausea—Epirubicin—testicular cancer	0.00315	0.00315	CcSEcCtD
Mepenzolate—Vomiting—Doxorubicin—testicular cancer	0.00312	0.00312	CcSEcCtD
Mepenzolate—Headache—Doxorubicin—testicular cancer	0.00307	0.00307	CcSEcCtD
Mepenzolate—Nausea—Doxorubicin—testicular cancer	0.00291	0.00291	CcSEcCtD
